文献速递消化、代谢与肾脏急症重症综合管理与镇静镇痛

静脉氨基酸用于肾脏保护的一项随机试验

A Randomized Trial of Intravenous Amino Acids for Kidney Protection.
PubMed 文献 · N Engl J Med · 2024-06-12
一句话结论成人心脏手术患者输注氨基酸(2 g/kg 理想体重/日,最多3天)可降低AKI发生率(26.9% vs 31.7%,RR 0.85)。

该多国双盲随机对照试验纳入3511例拟行体外循环心脏手术的成人患者,随机接受平衡氨基酸混合物(2 g/kg理想体重/日)或安慰剂(林格液)静脉输注,最多3天。主要终点为按KDIGO肌酐标准定义的AKI,氨基酸组474例(26.9%)vs 安慰剂组555例(31.7%)(RR 0.85;95%CI 0.77–0.94;P=0.002)。3期AKI分别为29例(1.6%)vs 52例(3.0%)(RR 0.56;95%CI 0.35–0.87)。肾脏替代治疗使用及其他次要终点、不良事件两组无实质性差异。

要点

  • 成人心脏手术(体外循环)患者中,氨基酸组AKI发生率26.9%(474例)vs 安慰剂组31.7%(555例),RR 0.85(95%CI 0.77–0.94;P=0.002)。
  • 氨基酸组3期AKI 1.6%(29例)vs 安慰剂组3.0%(52例),RR 0.56(95%CI 0.35–0.87)。
  • 肾脏替代治疗使用:氨基酸组1.4%(24例)vs 安慰剂组1.9%(33例)。
  • 其他次要终点及不良事件两组无实质性差异。
  • 方案为平衡氨基酸混合物2 g/kg理想体重/日静脉输注,最多3天;对照为林格液。

适用人群与场景

  • 拟行体外循环心脏手术的成人患者;多国22个中心、3个国家共纳入3511例(氨基酸组1759例,安慰剂组1752例)。

诊断标准与关键阈值

  • AKI定义采用KDIGO肌酐标准。
  • 3期AKI按原文报告为单独终点。

处置流程与药物剂量

  • 平衡氨基酸混合物静脉输注,剂量2 g/kg理想体重/日,最多3天;对照组输注安慰剂(林格液)。

研究设计与关键结果

  • 多国、双盲随机对照试验,22个中心、3个国家,3511例拟行体外循环心脏手术的成人患者,随机接受氨基酸(1759例)或安慰剂(1752例)。
  • 主要终点AKI:氨基酸组474例(26.9%)vs 安慰剂组555例(31.7%),RR 0.85(95%CI 0.77–0.94;P=0.002)。
  • 3期AKI:氨基酸组29例(1.6%)vs 安慰剂组52例(3.0%),RR 0.56(95%CI 0.35–0.87)。
  • 肾脏替代治疗使用:氨基酸组24例(1.4%)vs 安慰剂组33例(1.9%)。
  • 其他次要终点及不良事件两组无实质性差异。

证据类型、等级与局限

  • 证据类型:多国、双盲随机对照试验(PROTECTION,ClinicalTrials.gov NCT03709264);由意大利卫生部资助。
  • 局限:原文未报告局限性

对床旁实践的改变

  • 作者结论:在接受心脏手术的成人患者中,输注氨基酸可减少AKI的发生。
  • 原文未据此给出推荐。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Acute kidney injury (AKI) is a serious and common complication of cardiac surgery, for which reduced kidney perfusion is a key contributing factor. Intravenous amino acids increase kidney perfusion and recruit renal functional reserve. However, the efficacy of amino acids in reducing the occurrence of AKI after cardiac surgery is uncertain.

METHODS: In a multinational, double-blind trial, we randomly assigned adult patients who were scheduled to undergo cardiac surgery with cardiopulmonary bypass to receive an intravenous infusion of either a balanced mixture of amino acids, at a dose of 2 g per kilogram of ideal body weight per day, or placebo (Ringer's solution) for up to 3 days. The primary outcome was the occurrence of AKI, defined according to the Kidney Disease: Improving Global Outcomes creatinine criteria. Secondary outcomes included the severity of AKI, the use and duration of kidney-replacement therapy, and all-cause 30-day mortality.

RESULTS: We recruited 3511 patients at 22 centers in three countries and assigned 1759 patients to the amino acid group and 1752 to the placebo group. AKI occurred in 474 patients (26.9%) in the amino acid group and in 555 (31.7%) in the placebo group (relative risk, 0.85; 95% confidence interval [CI], 0.77 to 0.94; P = 0.002). Stage 3 AKI occurred in 29 patients (1.6%) and 52 patients (3.0%), respectively (relative risk, 0.56; 95% CI, 0.35 to 0.87). Kidney-replacement therapy was used in 24 patients (1.4%) in the amino acid group and in 33 patients (1.9%) in the placebo group. There were no substantial differences between the two groups in other secondary outcomes or in adverse events.

CONCLUSIONS: Among adult patients undergoing cardiac surgery, infusion of amino acids reduced the occurrence of AKI. (Funded by the Italian Ministry of Health; PROTECTION ClinicalTrials.gov number, NCT03709264.).

来源:N Engl J Med,查看原文。版权归原作者所有。

参考来源

  1. Landoni G, Monaco F, Ti LK, et al. A Randomized Trial of Intravenous Amino Acids for Kidney Protection. N Engl J Med. 2024. PMID: 38865168. doi:10.1056/NEJMoa2403769

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。